Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
The first FDA-approved Alzheimer’s blood test — and the power of real-world data to measure its impact
In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease, making early detection more accessible than ever. The Lumipulse test measures...
New study finds GLP-1 RA medications may significantly reduce risk of alcohol-related hospitalization
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target...
Understanding the impact of the COVID-19 pandemic on childhood MMR vaccination patterns
Timely receipt of the MMR vaccine for children has been declining since 2021, with just 76.9% of children receiving the MMR vaccine in 2024 on time. The odds of non-vaccination...
Shifting trends in TKA fixation: Real-world evidence on the changing landscape of cemented vs uncemented TKA
The percentage of uncemented total knee arthroplasties (TKAs) nearly doubled from 5.7% to 10.3% between 2018 and 2024. Readmission and revision rates were similar between...
FDA-approved anti-obesity GLP-1 RA prescription trends among adolescents
In collaboration with Reuters, Truveta Research explored trends in FDA-approved anti-obesity GLP-1 RA prescriptions among adolescents. Among the 1,265,399 adolescents (aged 12-17...
ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer
Authors: Wilson Lau, PhD ⊕Truveta, Inc, Bellevue, WA,, Youngwon Kim, PhD ⊕Truveta, Inc, Bellevue, WA, Sravanthi Paras, MD ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque,...
ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations
Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA,...
Prostate cancer is in the headlines — and early detection has never been more important
Each year, more than 34,000 men in the U.S. die from prostate cancer. While early-stage disease is often highly treatable, outcomes still vary widely — especially by race,...
How Truveta benchmarks AI model quality for clinical concept extraction
As machine learning models increasingly assist in interpreting patient records, understanding how to properly evaluate these models becomes crucial for ensuring reliable clinical...